Establishment of imatinib-resistant gastrointestinal stromal tumor cell subline and investigation of its sensitivity to the chemomotherapeutic agents
- Authors: Dunaev PD1, Boichuk SV1, Galembikova AR1, Khusnutdinov RR1
-
Affiliations:
- Kazan State Medical University
- Issue: Vol 98, No 6 (2017)
- Pages: 993-997
- Section: Experimental medicine
- Submitted: 04.12.2017
- Published: 15.12.2017
- URL: https://kazanmedjournal.ru/kazanmedj/article/view/7256
- DOI: https://doi.org/10.17750/KMJ2017-993
- ID: 7256
Cite item
Full Text
Abstract
About the authors
P D Dunaev
Kazan State Medical University
Email: boichuksergei@mail.ru
Kazan, Russia
S V Boichuk
Kazan State Medical University
Email: boichuksergei@mail.ru
Kazan, Russia
A R Galembikova
Kazan State Medical University
Email: boichuksergei@mail.ru
Kazan, Russia
R R Khusnutdinov
Kazan State Medical University
Email: boichuksergei@mail.ru
Kazan, Russia
References
- Jakhetiya A., Garg P.K., Prakash G. et al. Targeted therapy of gastrointestinal stromal tumours. World J. Gastrointest. Surg. 2016; 8 (5): 345-352. doi: 10.4240/wjgs.v8.i5.345.
- Boichuk S.V., Rausch J.L., Duensing A. New developments in management of gastrointestinal stromal tumors: regorafenib, the new player in the team. Gastrointestinal Cancer: Targets and Therapy. 2014; 4: 1-10. doi: 10.2147/GICTT.S20679.
- Gramza A.W., Christopher L.C., Michael C.H. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin. Cancer Res. 2009; 15 (24): 7510-7518. doi: 10.1158/1078-0432.CCR-09-0190.
- De Silva C.M., Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol. Oncol. Res. 2003; 9 (1): 13-19. PMID: 12704441.
- Verweij J., Casali P.G., Zalcberg J. et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364 (9440): 1127-1134. doi: 10.1016/S0140-6736(04)17098-0.
- Галембикова А.Р., Дунаев П.Д., Бойчук С.В. Оценка чувствительности гастроинтестинальных стромальных опухолей (ГИСТ) к химиопрепаратам различных групп. Электронный научный журнал «Современные проблемы науки и образования». 2015; 6. http://www.science-education.ru/130-23728 (дата обращения: 04.07.2017)
- Хуснутдинов Р.Р., Галембикова А.Р., Бойчук С.В. Получение клона клеток гастроинтестинальной стромальной опухоли с признаками множественной лекарственной устойчивости и оценка его свойств. Соврем. технол. в мед. 2016; 8 (4): 36-41. doi: 10.17691/stm2016.8.4.05.
- Pessetto Z.Y., Ma Y., Hirst J.J. et al. Drug repurposing identifies a synergisticcombination therapy with imatinib mesylate for gastrointestinal stromal tumor. Mol. Cancer Ther. 2014; 13 (10): 2276-2287. doi: 10.1158/1535-7163.MCT-14-0043.
- Taguchi T., Sonobe H., Toyonaga S. et al. Conventionaland molecular cytogenetic characterization of a newhuman cell line, GIST-T1, established from gastrointestinalstromal tumor. Lab. Invest. 2002; 82 (5): 663-665.